X-VIVO® 15 Serum-free Hematopoietic Cell Medium
X-VIVO® 15 Serum-free Hematopoietic Cell Medium
X-VIVO® 15, Serum-free hematopoietic cell medium, with L-Glutamine, gentamicin and phenol red, xenofree, 1 L
Want to request a quote or find our more information about this product including customization options? Please fill in your request and your local sales specialist will contact you.
Product Overview
X-VIVO® 15 is a high performing media that provides nutritionally adequate and balanced environments for a variety of hematopoietic cells including:
- T cells
- Natural killer cells (NK)
- Peripheral blood lymphocytes (PBL)
- Tumor infiltrating lymphocytes (TIL)
- Dendritic cells (DC)
- Human monocytes
- Macrophage cells
X-VIVO® 15 Media are mostly known for its ability to support the proliferation of purified CD3+ cells isolated from peripheral blood and human tumors making it well suited for CAR-T applications.
X-VIVO® 15 Media are similar in composition to X-VIVO® 10 Media but is better suited for rapidly growing cells, specifically cells of the immune system.
THIS PRODUCT IS NOT FOR USE IN GMP MANUFACTURING, NOR HUMAN OR ANIMAL IN VIVO USE, INCLUDING USE AS A DILUENT OR AS AN EXCIPIENT, OR FOR DIAGNOSTIC USE. This product is for research use only.
Request More InfoApplications
- Proliferation of peripheral blood lymphocytes
- Proliferation of tumor infiltrating lymphocytes
- Cryopreservation of human tissue
- Cultivation of human monocytes and macrophages
- Cultivation of stem cells
- Cultivation of dendritic cells
Storage and Content
1L bottleSDS, CoA, and Instructions
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
CAR T cells in Cancer Therapy
A poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years. -
A Non-Viral Method for Modifying and Expanding Primary T Cells
Learn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.
